Lantern Pharma CEO Details AI Platform's Role in Accelerating Cancer Drug Development

Lantern Pharma (NASDAQ: LTRN) is leveraging artificial intelligence to transform cancer drug development through its proprietary platform that learns, reads scientific literature, models molecules, predicts patient response, and suggests new therapeutic indications. CEO Panna Sharma explained in a FintechTV interview that the company's AI technology is compressing development timelines and cost structures across oncology, representing a significant advancement in how cancer treatments are discovered and developed.

The company's RADR platform processes over 200 billion oncology-focused data points using more than 200 machine learning algorithms to identify new drugs and reposition existing molecules for high-unmet-need oncology indications. This AI-driven approach enables Lantern to solve complex problems in drug development that have traditionally required extensive time and financial resources. Sharma emphasized that the platform's ability to self-learn and predict outcomes is creating new efficiencies in the drug discovery process.

Lantern currently has three clinical-stage oncology candidates in development, including a Phase 2 trial targeting non-smoker non-small cell lung cancer and a program focused on cancers with DNA damage repair deficiency using synthetic lethality approaches. The company anticipates upcoming data milestones from its LP-184 program and plans to make its AI platform commercially available to drug developers worldwide. This expansion could potentially accelerate cancer research across the pharmaceutical industry.

According to company information available at https://ibn.fm/LTRN, Lantern's AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential exceeding $15 billion. The company's approach represents a shift toward what Sharma describes as a golden era of medicine, where artificial intelligence, data analytics, and robotics enable faster, cheaper, and more personalized cancer treatments. This technological advancement comes at a critical time when the healthcare industry faces increasing pressure to develop effective therapies more efficiently.

The full interview with CEO Panna Sharma discussing these developments can be viewed at https://ibn.fm/ZvbMK. Lantern's work demonstrates how AI is becoming increasingly integral to pharmaceutical research, particularly in oncology where treatment personalization and development speed are paramount. The company's progress highlights the growing intersection of technology and healthcare, suggesting potential paradigm shifts in how future medical breakthroughs will be achieved.